Latest News

New Phase 3 data show a single-tablet regimen of bictegravir/lenacapavir could finally bring one-pill simplicity to long-term HIV survivors locked into complex regimens by decades of drug resistance. The science is closing the treatment gap. Will our policy systems do the same?

States are rationing HIV medications through prior auth and formulary cuts to solve ADAP budget crises — a strategy that costs more, drives resistance, and concentrates harm on the most vulnerable.

Insurance companies deploy AI algorithms for automated prior authorization denials, restricting patient access to prescribed treatments.

How payor cost-containment strategies drive health disparities and limit care access.

Research proves alcohol doesn't reduce DAA efficacy for HCV, yet payers continue restricting treatment.

Payers face regulatory scrutiny for systematic coverage denials and prior authorization abuse.

HCV Medicaid Access dashboard 2023 update: progress in eliminating treatment restrictions by state.

Payers use prior authorization and step therapy to deny care, driving health disparities.

Preview of 2023 federal regulatory priorities: Section 1557, IRA implementation, and prior authorization reform.

ADAP Fireside Chat addresses counterfeit medications, 340B reform, and public health workforce sustainability.

Only 35% of privately insured and 23% of Medicaid patients initiate HCV treatment due to payer barriers.

PrEP access remains limited by payer practices like prior authorizations despite ACA coverage requirements.

AMA survey: 93% of providers say prior authorizations delay care with 91% reporting negative clinical impact.

FDA extends Cabenuva to 2-month injections but insurance barriers continue to restrict patient access.

Examines CMS's rebate rule on copay accumulator programs that block patient assistance from counting toward deductibles.